Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): First results of phase II trial GORTEC 2008-03.
2011 ◽
Vol 29
(15_suppl)
◽
pp. 5567-5567
◽
Keyword(s):
Phase Ii
◽